Inovio Pharmaceuticals financials
$1.11−5.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $65.3K | $117.0K | $0.00 | $100.8K | $0.00 | $102.7K | $388.4K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $65.3K | $117.0K | $0.00 | $100.8K | $0.00 | $102.7K | $388.4K |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% | — | 100.0% | — | 100.0% | 100.0% |
| Operating income | -$18.6M | -$21.9M | -$17.5M | -$21.2M | -$23.1M | -$25.1M | -$20.4M | -$27.3M | -$33.2M | -$31.5M | -$27.4M | -$35.6M |
| Net income | -$6.0M | -$19.7M | $3.8M | -$45.5M | -$23.5M | -$19.7M | -$19.4M | -$25.2M | -$32.2M | -$30.5M | -$25.0M | -$33.9M |
| Net margin | — | — | — | — | — | −30140.5% | −16566.4% | — | −31993.3% | — | −24357.9% | −8734.8% |
| Diluted EPS | $-0.07 | $-0.28 | $0.06 | $-0.87 | $-0.61 | $-0.51 | $-0.65 | $-0.89 | $-1.19 | $-1.31 | $-1.10 | $-1.52 |
| EBITDA | -$18.3M | -$21.6M | -$17.1M | -$20.9M | -$22.7M | -$24.7M | -$20.0M | -$26.9M | -$32.7M | -$31.1M | -$26.8M | -$24.4M |
| Operating cash flow | -$18.0M | -$21.6M | -$19.4M | -$21.6M | -$20.8M | -$26.9M | -$19.7M | -$27.4M | -$28.2M | -$28.8M | -$26.3M | -$29.1M |
| Free cash flow | -$18.0M | -$21.6M | -$19.5M | -$21.6M | -$20.8M | -$26.9M | -$19.7M | -$27.4M | -$28.7M | -$28.8M | -$26.3M | -$29.1M |
| Diluted shares | 81.6M | 69.1M | 57.9M | 52.2M | 38.8M | 38.6M | 30.0M | 28.1M | 27.2M | 23.3M | 22.7M | 22.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $31.5M | $26.3M | $44.3M | $36.6M | $24.4M | $39.9M |
| Short-term investments | $5.1M | $11.4M | $14.2M | $14.2M | $23.2M | $28.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $49.4M | $49.8M | $74.3M | $69.4M | $68.2M | $87.3M |
| Total liabilities | $45.0M | $43.7M | $50.2M | $77.1M | $39.7M | $36.0M |
| Shareholders' equity | $4.4M | $6.1M | $24.1M | -$7.7M | $28.5M | $51.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology